Virusboy acho que você nunca leu um estudo científico na vida, o que é o nível normal do brasileiro médio, mas vamos lá vou lhe ajudar a irrigar a aridez de sua ignorância abissal.
Vamos aos resultados do paper:
Results
62 patients were identified as having COVID-19 and enrolled in this study, none quit (Figure 1). As
shown in Table 1, For all patients, the age was 44.7 (15.3) years old, 46.8% (29 of 62) were male and
53.2% (33 of 62) were female. Patients were randomly assigned into two groups. There was no
significant difference in the age and sex distribution between the two groups of patients, but there are
significant differences in TTCR between the two groups.
1)For fever, 17 patients in the control group and 22 patients in the HCQ treatment group had a fever in day 0. Compared with the control group [3.2 (1.3)
days], the body temperature recovery time was significantly shortened in the HCQ treatment group [2.2
(0.4) days].
2)For cough, 15 patients in the control group and 22 patients in the HCQ treatment group had
a cough in day 0, The cough remission time was significantly reduced in the HCQ treatment group.
3)Notably, a total of 4 of the 62 patients progressed to severe illness, all of which occurred in the control
group not receiving HCQ treatment.
For adverse effects, it should be noted that there were two patients with mild adverse reactions in the HCQ treatment group, one patient developed a rash, and one patient
experienced a headache, none severe side effects appeared among them.
4)To further explore the effect of HCQ on pneumonia, we compared and analyzed the chest CT of patients on day 0 and day 6.
In our study, pneumonia was improved in 67.7% (42/62) of patients, with 29.0% moderately absorbed and 38.7% significantly improved.
Surprisingly, a larger proportion of patients with improved pneumonia in the HCQ treatment group (80.6%, 25 of 31) compared with the control group (54.8%, 17 of 31).
Besides, 61.3% of patients in the HCQ treatment group had a significant pneumonia absorption.
Agora vou estratificar os resultados pra seu cerebrozinho entender por pontos, se mesmo assim você não entender, agende uma consulta neurológica:
1) O sintoma febre
durou significativamente menos tempo nos pacientes que receberam hidroxicloroquina.
2)A duração do sintoma tosse
durou significativamente menos nos pacientes que receberam hidroxicloroquina.
3)No grupo que estava recebendo hidroxicloroquina
não houve progressão da doença para as formas severas, diferente no que ocorreu no grupo que recebia placebo.
4) No quesito melhora da pneumonia comparando o dia 0 e o dia 6 de evolução,
80,6% dos pacientes que usaram hidroxicloroquina tiveram melhora vs apenas
54,8% dos pacientes que não usaram hidroxicloroquina .
O que esses dados indicam pra você, Virusboy? Que funciona ou não funciona?
Mais que isso não posso fazer por você.
